Form 4: Integrated Biopharma Co-CEO Kay Acquires Stock Options

Integrated Biopharma's Co-CEO Christina Kay acquired 140,000 stock options with a $0.35 exercise price, vesting over three years.

Summary

• Christina Kay, Co-Chief Executive Officer, Director, and 10% Owner of Integrated Biopharma Inc. (INBP), reported the acquisition of derivative securities.
• The transaction involved 140,000 stock options with an exercise price of $0.35 per share.
• These options were granted on December 9, 2025, and are exercisable into 140,000 shares of Common Stock.
• The options vest in three equal annual installments, with the first installment vesting on December 9, 2026.
• The expiration date for these stock options is December 9, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive for aligning management incentives with shareholder value, indicating confidence in future performance.

Positives

• The grant of stock options to Co-CEO Christina Kay aligns management's long-term interests with those of shareholders, incentivizing performance.
• The exercise price of $0.35 provides a clear benchmark for future stock performance required for the options to be in-the-money.

Related Party Transactions

• The transaction involves the grant of stock options to Christina Kay, who is the Co-Chief Executive Officer, a Director, and a 10% Owner of Integrated Biopharma Inc., making it an insider transaction.

Stakeholder Impact

• Shareholders: The option grant aims to align the Co-CEO's financial interests with long-term shareholder value creation.
• Management: Provides a performance-based incentive for the Co-CEO.

Next Steps

• The stock options will vest in three equal annual installments, with the next vesting event occurring on December 9, 2026.

Key Dates

Keywords

INBP, Integrated Biopharma, Christina Kay, stock options, insider transaction, Form 4, executive compensation, derivative securities